BioMelbourne Network
Progressing BioIndustry
News and Opinions
2013
April
Alchemia SPP Closes Heavily Oversubscribed
April 12 2013. Australian drug discovery and development company Alchemia Limited (ASX: ACL) (“Alchemia” or the “Company”) has successfully closed its share purchase plan (“SPP”) heavily oversubscribed.After scaling back demand, the Company has raised $2.75 million. This capital is in addition to the $10.2 million recently raised via an institutional placement. Following a scale back and round... read more…
Draft Pharmaceutical Patents Review Report Released
April 9 2013. DRAFT PHARMACEUTICAL PATENTS REVIEW REPORT RELEASED - BAD NEWS FOR RESEARCH BASED PHARMACEUTICAL INDUSTRY
By Michael Caine and Mark Roberts, Davies Collison Cave On 2 April 2013 the Pharmaceutical Patents Review Panel released its draft report for public comment. While the findings and recommendations in the Report are not unexpected, given the make up of the panel and the shor... read more…
Strategic Review of Health and Medical Research
April 5 2013. The Minister for Health, the Hon Tanya Plibersek MP, has today released the report of the McKeon Review - Strategic Review of Health and Medical Research – Better Health through Research.The full report can be accessed by clicking hereThe summary version of the report can be accessed by clicking hereReview of Health and Medical Research in AustraliaThe Strategic Review of Health ... read more…
Phosphagenics: Oxycodone Patch Resumes Clinical Development
April 5 2013. Australian drug delivery technology company, Phosphagenics Limited (ASX: POH, OTCQX: PPGNY), will be returning to the clinic with its oxycodone TPM® transdermal patch.The Company has received ethics approval to conduct a further clinical trial at the Royal Adelaide Hospital’s independent CMAX facility. The trial is designed to assess the profile of the new patch and form an integ... read more…
Up to $10 million in cancer research funding available through the Australian Cancer Research Foundation
April 3 2013. The Australian Cancer Research Foundation (ACRF) has begun accepting applications for their 2013 annual Cancer Research Grant Round.The ACRF provides major grants between $1.5 and $5 million to develop state-of-the-art, collaborative research centres and purchase advanced technologies and equipment.Grants of this magnitude are not available from any other private funding body in ... read more…
Phosphagenics Extends Agreement with Japanese Partner
April 2 2013. Australian drug delivery technology company Phosphagenics Limited (ASX: POH, OTCQX: PPGNY) has extended its collaboration with its high calibre Japanese partner, Nippon Zoki Pharmaceutical Co., Ltd., to develop a new anti-inflammatory product to treat acute and chronic pain for the US market.The parties are progressing their collaboration arrangements to develop a more effective ... read more…
Allied Lodges 510(K) with FDA for CardioCel® Marketing Approval
April 2 2013. Allied Healthcare Group (ASX: AHZ) today announced that on the 29th of March, US time, the Company lodged its Premarket Notification 510(k) Submission for CardioCel® in the United States (U.S). The FDA 510(K) submission is a major step in Allied’s strategy to gain marketing approval for CardioCel® in the U.S.CardioCel® is a cardiovascular tissue patch used to repair heart deformi... read more…
March
Spinifex Receives $1.5m in R&D Tax Incentive for Research Activities Related to the Discovery of Treatments for Pain
March 29 2013. Spinifex Pharmaceuticals, an Australian pain drug development company, today announces it has received an approximately AUS$1.5 million R&D tax incentives cash refund for research activities relating to the discovery of new drugs for the treatment and management of pain. The R&D Incentive Program is an annual scheme, jointly administered by AusIndustry and the Australian Taxatio... read more…
Oxymorphone Patch Meets Phase 1 End Points
March 28 2013. Australian drug delivery technology company, Phosphagenics Limited (ASX: POH, OTCQX: PPGNY), advises that it has achieved all end points of its important Phase 1 trial of its oxymorphone patch by successfully delivering the powerful opioid into the bloodstream via its patented TPM® transdermal skin patch.The single dose Phase 1 study, conducted at the CMAX independent clinical r... read more…
Office of PM: Changes to the Ministry
March 25 2013. Today Gary Gray joins the Cabinet as Minister for Resources and Energy, Minister for Tourism and Minister for Small Business.
He has been a tireless advocate for business in his own community and in Western Australia and will bring that purpose to promoting the interests of the tourism sector and small business.
His current roles as Special Minister of State and Minister for t... read more…
